Antithrombotic treatment of deep vein thrombosis;Therapie der beinvenenthrombose: Wann welche substanzen?

Internist

Volumn 45, Issue 12, 2004, Pages 1345-1355

  Bauersachs, R M ^a,b  

^a KLINIKUM DARMSTADT   (Germany)

^b Klinikum   (Germany)

Author keywords

Anticoagulation; Deep vein thrombosis; Heparin; Kantagonists; Thromboembolism; Vitamin

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; DANAPAROID; EMBOLEX; ENOXAPARIN; FONDAPARINUX; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PHENPROCOUMON; REVIPARIN; TINZAPARIN; WARFARIN; XIMELAGATRAN;

ANTIPHOSPHOLIPID SYNDROME; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LEG THROMBOSIS; RECURRENT DISEASE; REVIEW;

ADMINISTRATION, ORAL; ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME; VENOUS THROMBOSIS; VITAMIN K;

EID: 12344289043     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-004-1302-8     Document Type: Review

References (38)

1. van Den Belt AG, Prins MH, Lensing AW, Castro AA, Clark OA, Atallah AN, Burihan E (2000) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev: CD001100
2. van Dongen CJ, Mac Gillavry MR, Prins MH (2003) Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev: CD003074
3. Bauersachs RM, Lindhoff-Last E, Wolff U, Ehrly AM (1998) Aktuelles Management der tiefen Venenthrombose. Med Welt 49: 194-215
4. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, KaaJa R (2002) Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 87: 182-186
5. Greinacher A (2003) Heparininduzierte Thrombozytopenie. Dtsch Ärztebl 100: A-2220-2229
6. Montalescot G, Philippe F, Ankri A et al. (1998) Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 98: 294-299
7. Hirsch D, Lee T, Morrison R, Carlson, Goldhaber S (1996) Shortened hospitalization by means of adjusted-dose subcutaneous heparin for deep venous thrombosis. Am Heart J 131: 276-278
8. Büller HR, Davidson BL, Decousus H et al. (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140: 867-873
9. Büller HR, Davidson BL, Decousus H et al. (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349: 1695-1702
10. Magnani H (1993) Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 70: 554-556
11. Schulman S, Rhedin AS, Lindmarker P et al. for the Duration of Anticoagulation Trial Study Group (1995) Comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332: 1661-1665
12. Bauersachs RM (2003) Was ist gesichert in der Therapie? Therapie und Sekundärprophylaxe der venösen Thromboembolie mit Vitamin-K- Antagonisten. Internist (Berl) 44: 1491-1499
13. Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95: 315-328
14. Agnelli G (2004) Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: no. J Thromb Haemost 2: 1038-1040
15. Palareti G, Leali N, Coccheri S et al. (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348: 423-428
16. Kearon C, Ginsberg JS, Kovacs MJ et al. (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349: 631-639
17. Ridker P et al. for the PREVENT Investigators (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348: 1425-1434
18. Kearon C, Ginsberg JS, Kovacs M et al. (2003) Influence of thrombophilia on efficacy of warfarin for prevention of recurrent venous thromboembolism: results from a randomized trial. J Thromb Haemost 1 [Suppl]: OC002
19. Crowther MA, Ginsberg JS, Julian J et al. (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349: 1133-1138
20. Vink R, Kraaijenhagen RA, Levi M, Buller HR (2003) Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model. J Thromb Haemost 1: 2523-2530
21. Lindhoff-Last E, Sohn C, Ehrly AM, Bauersachs RM (2000) Aktuelles Management der ThromboemboNe in Schwangerschaft und Wochenbett. Zentralbl Gynäkol 122: 4-16
22. Arcelus JI, Caprini JA, Monreal M, Suarez C, Gonzalez-Fajardo J (2003) The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. J Vasc Surg 38: 916-922
23. van der Heijden JF, Hutten BA, Buller HR, Prins MH (2002) Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev: CD002001
24. Pineo GF, Hull RD (2003) Tinzaparin in the treatment of venous thromboembolism. Expert Opin Pharmacother 4: 2355-2362
25. Meyer G, Marjanovic Z, Valcke J et al. (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162: 1729-1735
26. Lee AY, Levine MN, Baker RI et al. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146-153
27. Ginsberg JS, Bates SM (2003) Management of venous thromboembolism during pregnancy. J Thromb Haemost 1: 1435-1442
28. Sanson BJ, Lensing AWA, Prins MH et al. (1999) Safety of low-molecular-weight heparin in pregnancy: A systematic review. Thromb Haemost 81: 668-672
29. Hach-Wunderle V, Bauersachs R, Landgraf H, Schellong S, Schweizer J, Wuppermann T (2002) Leitlinien der Deutschen Gesellschaft für Angiologie: Venöse Thromboembolie. VASA S60: 1-19
30. Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, Geerts W, Kovacs M, Weitz JI, Robinson KS, Whittom R, Couture G (2000) Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 343: 1439-1444
31. Greer IA (2004) Prevention of venous thromboembolism in pregnancy. Eur J Med Res 9: 135-145
32. Bauersachs RM, für die EThlG Trialist Group (2004) EThlG Studie: Risikoschwangere erfolgreich antikoagulieren. Vascular Care 6: 28-41
33. Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S (2003) A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 1: 41-47
34. Huisman MV, on behalf of The THRIVE II&V Investigators (2003) Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. J Thromb Haemost 1 [Suppl 1 ]: OC003
35. Schulman S, Wahlander K, LundstromT, Clason SB, Eriksson H (2003) Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349: 1713-1721
36. The Persist Investigators (2004) A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2: 47-53
37. Kearon C, Hirsh J (1997) Management of anticoagulation before and after elective surgery. N Engl J Med 336: 1506-1511
38. Ridker PM (2004) Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yes. J Thromb Haemost 2: 1034-1037